Prometic Secures $10M for GMP Facility
By Catherine Shaffer
Thursday, September 12, 2013
Prometic Life Sciences Inc., of Laval, Quebec, will earmark a portion of the proceeds from a $10 million financing from Thomvest Seed Capital Inc. to commission its GMP facility for manufacture of plasma-derived orphan drugs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.